Susan Knight - SurModics Independent Director
| SRDX Stock | USD 34.55 1.22 3.66% |
Director
Ms. Susan E. Knight is an Independent Chairman of the Board of the Company. She was a director of the Company since 2008. From 2001 until 2014, she served in a variety of senior leadership positions at MTS Systems Corporation, a leading global supplier of test systems and industrial position sensors. From 2011 to 2014, she served as Senior Vice President and Chief Financial Officer of MTS. From 2001 to 2011, she served as Vice President and Chief Financial Officer of MTS. Prior to her positions with MTS, from 1977 to 2001, Ms. Knight served in various executive and management positions with Honeywell Inc., last serving as the Chief Financial Officer of the global Home and Building Controls division. Since December 2017, she has served on the Childrens Minnesota Hospital Board Finance Committee, and Ms. Knight was appointed to the Mairs Power Funds Trust Board of Trustees, effective January 2018. Ms. Knight served on the board of the Greater Metropolitan Housing Corporation from 2000 to 2016, where she was the Chair of the Board from 2012 to 2015, and Chair of the Audit Committee from 2003 to 2012. Ms. Knight also served on the board of Plato Learning, Inc., from 2006 to 2010, where she served on the Audit Committee, including as Chair from 2009 to 2010, and on the Governance and Nominating and a Special Committee from 2009 to 2010. since 2015.
| Age | 63 |
| Tenure | 9 years |
| Address | 9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523 |
| Phone | 952 500 7000 |
| Web | https://www.surmodics.com |
Susan Knight Latest Insider Activity
Tracking and analyzing the buying and selling activities of Susan Knight against SurModics stock is an integral part of due diligence when investing in SurModics. Susan Knight insider activity provides valuable insight into whether SurModics is net buyers or sellers over its current business cycle. Note, SurModics insiders must abide by specific rules, including filing SEC forms every time they buy or sell SurModics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Susan Knight 3 days ago Acquisition by Susan Knight of 1944 shares of SurModics subject to Rule 16b-3 |
SurModics Management Efficiency
The company has return on total asset (ROA) of 0.0447 % which means that it generated a profit of $0.0447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0481 %, meaning that it created $0.0481 on every $100 dollars invested by stockholders. SurModics' management efficiency ratios could be used to measure how well SurModics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.01 in 2024. Return On Capital Employed is likely to drop to 0.03 in 2024. At this time, SurModics' Other Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 60.7 M in 2024, whereas Total Assets are likely to drop slightly above 140.7 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| George Philip | Paragon 28 | 67 | |
| Aleksandr Dybal | Si Bone | 51 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| Igor Fedorov | Si Bone | 53 | |
| Aleksandr Medvedev | Si Bone | 62 | |
| Heyward Donigan | Si Bone | 57 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| Lee Jones | Electromed | 60 | |
| Timothy Petersen | Si Bone | 53 | |
| Keith Valentine | Si Bone | 50 | |
| Bryan Hughes | Orthopediatrics Corp | 40 | |
| Peter Robinson | Paragon 28 | 64 | |
| Karen Licitra | Si Bone | 58 | |
| Alexis Lukianov | Orthofix Medical | 61 | |
| Glenn Larsen | Anika Therapeutics | 62 | |
| Timothy Davis | Si Bone | 48 | |
| Bernie Berry | Orthopediatrics Corp | 65 | |
| Brian Concannon | CONMED | 62 | |
| Igor Antonov | Si Bone | 66 | |
| Sharon OKane | LivaNova PLC | 49 | |
| Susan Vogt | Anika Therapeutics | 66 | |
Management Performance
| Return On Equity | 0.0481 | ||||
| Return On Asset | 0.0447 |
SurModics Leadership Team
Elected by the shareholders, the SurModics' board of directors comprises two types of representatives: SurModics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SurModics. The board's role is to monitor SurModics' management team and ensure that shareholders' interests are well served. SurModics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SurModics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Arens, VP of Corporate Devel. and Strategy | ||
| Thomas Greaney, Vice President - Operations, General Manager, SurModics Ireland | ||
| Charles Olson, Sr. VP and General Manager of Medical Device | ||
| Susan Knight, Independent Director | ||
| Gary Maharaj, CEO and President and Director | ||
| Andrew LaFrence, CFO, Vice President | ||
| Ronald Kalich, Independent Director | ||
| Lisa Heine, Director | ||
| John Manders, Corporate Controller and Principal Accounting Officer | ||
| Shawn McCormick, Independent Director | ||
| Gregg Sutton, Vice President - Research & Development | ||
| Teri Sides, Senior Vice President Chief Marketing Officer | ||
| John Benson, Independent Director | ||
| Jose Bedoya, Independent Director | ||
| Joseph Stich, VP and General Manager of In-Vitro Diagnostics | ||
| David Dantzker, Independent Director | ||
| Gordon Weber, General Legal | ||
| Teryl Sides, Senior Interventions | ||
| Bryan Phillips, Sr. VP of Legal and HR, General Counsel and Corporate Secretary |
SurModics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SurModics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0481 | ||||
| Return On Asset | 0.0447 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 364.42 M | ||||
| Shares Outstanding | 14.24 M | ||||
| Shares Owned By Insiders | 3.74 % | ||||
| Shares Owned By Institutions | 91.39 % | ||||
| Number Of Shares Shorted | 472.89 K | ||||
| Price To Earning | 69.21 X |
Currently Active Assets on Macroaxis
When determining whether SurModics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SurModics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Surmodics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Surmodics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SurModics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy SurModics Stock please use our How to Invest in SurModics guide.Note that the SurModics information on this page should be used as a complementary analysis to other SurModics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for SurModics Stock analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is SurModics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SurModics. If investors know SurModics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SurModics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.358 | Earnings Share 0.39 | Revenue Per Share 9.829 | Quarterly Revenue Growth 0.225 | Return On Assets 0.0447 |
The market value of SurModics is measured differently than its book value, which is the value of SurModics that is recorded on the company's balance sheet. Investors also form their own opinion of SurModics' value that differs from its market value or its book value, called intrinsic value, which is SurModics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SurModics' market value can be influenced by many factors that don't directly affect SurModics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SurModics' value and its price as these two are different measures arrived at by different means. Investors typically determine if SurModics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SurModics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.